- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04502355
Voriconazole-Induced QT Interval Prolongation: A Prospective Study
August 4, 2020 updated by: Rabin Medical Center
The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients.
A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes.
Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published.
This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.
Study Overview
Status
Unknown
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Petah Tikva, Israel
- Recruiting
- Schneider childrens medical center of Isreal
-
Contact:
- Odelia Matz
- Phone Number: +972-54-4634718
- Email: odeliama1@clalit.org.il
-
Contact:
- Liat Ashkenazi-Hoffnung, MD
- Phone Number: +972-54-4749345
- Email: liata3@clalit.org.il
-
Principal Investigator:
- Liat Ashkenazy-Hoffnung, MD
-
Sub-Investigator:
- Itzhak Levy, MD, MPH
-
Sub-Investigator:
- Havatzelet Yarden-Bilavsky, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (Child, Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Children aged 0-20 years treated with oral or IV voriconazole at the Schneider Children's Medical Center from Oct 31st 2016.
Description
Inclusion Criteria:
- oral or IV treatment with voriconazole
Exclusion Criteria:
- No data prior to initiation of voriconazole treatment on QT interval (baseline ECG)
- Renal insufficiency or dialysis treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
QT interval prolongation
Time Frame: up to three months of treatment
|
up to three months of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 31, 2016
Primary Completion (Anticipated)
December 31, 2020
Study Completion (Anticipated)
December 31, 2020
Study Registration Dates
First Submitted
August 4, 2020
First Submitted That Met QC Criteria
August 4, 2020
First Posted (Actual)
August 6, 2020
Study Record Updates
Last Update Posted (Actual)
August 6, 2020
Last Update Submitted That Met QC Criteria
August 4, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 0483-16-RMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Voriconazole Induced QT Interval Prolongation
-
Indiana UniversityPurdue UniversityCompletedQT Interval ProlongationUnited States
-
Peking University Third HospitalUnknown
-
Lexicon PharmaceuticalsCompleted
-
Medical University of GdanskEnrolling by invitationQT Interval | Paravertebral BlockPoland
-
Food and Drug Administration (FDA)Spaulding Clinical Research LLCCompletedPharmacokinetics | Pharmacodynamics | Drug-induced QT ProlongationUnited States
-
Food and Drug Administration (FDA)Spaulding Clinical Research LLCCompletedPharmacokinetics | Pharmacodynamics | Drug-induced QT ProlongationUnited States
-
Food and Drug Administration (FDA)Spaulding Clinical Research LLCCompletedPharmacokinetics | Pharmacodynamics | Drug-induced QT Prolongation
-
Duzce UniversityCompletedQt Interval, Variation inTurkey
-
University of SunderlandSheffield Hallam University; Newcastle University; Teesside UniversitySuspendedQt Interval, Variation inUnited Kingdom
-
Samsung Medical CenterCompletedQt Interval, Variation inKorea, Republic of